2024
LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Llovet J, Finn R, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Li H, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, El-Khoueiry A, Vogel A, Peng X, Mody K, Dubrovsky L, Kudo M. LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study. Annals Of Oncology 2024, 35: s1229. DOI: 10.1016/j.annonc.2024.08.2277.Peer-Reviewed Original ResearchTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Ibrahim S, Fortune B, Talenfeld A, Madoff D, Johnson M, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. American Journal Of Roentgenology 2024, 223: e2431272. PMID: 38899842, DOI: 10.2214/ajr.24.31272.Peer-Reviewed Original ResearchEarly-stage hepatocellular carcinomaHepatocellular carcinomaPost-procedure periodIndex procedureOut-of-pocket costsPatient out-of-pocket costsDrivers of high costsDays post-procedureSubgroup of patientsTreated with ablationPropensity-matched subgroupsU.S. population-based studyPopulation-based studySurgical resectionMultivariate linear regression modelSurgical treatmentPrognostic indicatorPost-procedureTreatment modalitiesTreatment optionsSEER-MedicareResectionMultivariate analysisTransplantationPropensity-scoreImage-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy?
Chan S, Cornman-Homonoff J, Lucatelli P, Madoff D. Image-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy? Clinical Imaging 2024, 111: 110185. PMID: 38781614, DOI: 10.1016/j.clinimag.2024.110185.Peer-Reviewed Original ResearchLiver venous deprivationPortal vein embolizationRadiation lobectomyVein embolizationResection of HCCMinimally invasive techniquesStandard of careHepatic malignanciesLiver remnantLiver insufficiencySurgical candidacySurgical techniqueHepatocellular carcinomaInvasive techniquesHepatic functionPercutaneous strategiesResectionPatient's likelihoodLobectomyEmbolizationLiverPatientsFLRCarcinomaMalignancyEffect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma.
Shewarega A, Santana J, Nam D, Berz A, Tefera J, Kahl V, Mishra S, Coman D, Duncan J, Roberts S, Wetter A, Madoff D, Chapiro J. Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8+ T-Cell Infiltration in Murine Hepatocellular Carcinoma. Radiology 2024, 310: e232365. PMID: 38349244, PMCID: PMC10902598, DOI: 10.1148/radiol.232365.Peer-Reviewed Original ResearchConceptsT cell infiltrationCD8<sup>+</sup> T cellsMatrix metalloproteinase inhibitionT cellsHepatocellular carcinomaMatrix metalloproteinase inhibitorsMatrix metalloproteinasesResidual tumorCXCR3<sup>+</sup> CD8<sup>+</sup> T cellsCytotoxic CD8<sup>+</sup> T cell infiltrationIntratumoral CD8+ T cell infiltrationCD8+ T cell infiltrationCD8<sup>+</sup> T cell infiltrationMouse model of hepatocellular carcinomaEarly-stage hepatocellular carcinomaImage-guided tumor ablationUnpaired Student's <i>t</i> testModel of hepatocellular carcinomaFirst-line therapyMurine hepatocellular carcinomaT cell subsetsTumor-associated macrophagesMurine HCC modelLocal immune responseFemale BALB/c mice
2023
Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Beyond Survival: Adverse Events and Care Delivery Outcomes after Early Liver Cancer Treatment in a Nationally Representative Cohort. Journal Of Vascular And Interventional Radiology 2023, 34: 1997-2005.e3. PMID: 37468093, DOI: 10.1016/j.jvir.2023.07.010.Peer-Reviewed Original ResearchConceptsLiver transplantSurgical resectionHepatocellular carcinomaLT cohortBiliary injuryReadmission ratesAbscess formationIntensive care unit-level careLess healthcare utilizationNationally Representative CohortInitial hospital stayICU-level careAdverse event ratesEnd Results ProgramSmall hepatocellular carcinomaCare delivery outcomesFisher's exact testHealthcare Common Procedure Coding SystemChi-square testLow-intensity careLiver cancer treatmentPostprocedural hemorrhageHospital stayAdverse eventsSecondary outcomes
2022
Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver
Santana J, Shewarega A, Nam D, Kahl V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 404-408.e1. PMID: 36473611, PMCID: PMC11037556, DOI: 10.1016/j.jvir.2022.11.026.Peer-Reviewed Original ResearchConceptsLiver cirrhosisMale New Zealand white rabbitsRabbit liver tumor modelCirrhotic liver backgroundReproducible tumor growthVX2 liver cancerLeft hepatic lobeNew Zealand white rabbitsDuration of treatmentLiver tumor modelCross-sectional imagingVX2 rabbit liver tumor modelZealand white rabbitsHepatic lobeHistopathological evaluationMajor underlying factorHepatic tumorsIntragastric administrationHepatocellular carcinomaLiver tumorsLiver cancerCirrhosisUnmet needTumor growthVX2 tumorsDefining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study
Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, Bilbao JI, Bouvier A, Chapiro J, Chiesa C, Decaens T, Denys A, Duran R, Edeline J, Garin E, Ghelfi J, Helmberger T, Irani F, Lam M, Lewandowski R, Liu D, Loffroy R, Madoff DC, Mastier C, Salem R, Sangro B, Sze D, Vilgrain V, Vouche M, Guiu B, Ronot M. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 50: 921-928. PMID: 36282299, DOI: 10.1007/s00259-022-06002-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyTextbook outcomeInternal radiation therapyHepatocellular carcinomaRadiation therapyPatient-important outcomesLarge observational studiesNuclear medicine physiciansEntire intervention processRandomized trialsRoutine careResultsA totalObservational studyMultistep interventionMedicine physiciansInterventional radiologistsSenior authorClinical roundsCarcinomaTherapyInterventionOutcomesLong-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort
Charalel RA, Mushlin AI, Li D, Mao J, Ibrahim S, Carlos R, Kwan SW, Fortune B, Talenfeld AD, Brown RS, Madoff DC, Johnson MS, Sedrakyan A. Long-Term Survival After Surgery Versus Ablation for Early Liver Cancer in a Large, Nationally Representative Cohort. Journal Of The American College Of Radiology 2022, 19: 1213-1223. PMID: 36208842, DOI: 10.1016/j.jacr.2022.07.010.Peer-Reviewed Original ResearchConceptsCancer-specific survivalSurgical resectionSmall hepatocellular carcinomaPrior treatment groupsHepatocellular carcinomaSurvival outcomesTreatment groupsSR groupPrior treatmentEnd Results Program-MedicarePropensity-matched hazard ratiosPropensity score-matched comparisonMedian study followNationally Representative CohortCancer-specific mortalityDisease-free survivalCox regression analysisKaplan-Meier curvesLog-rank testEarly liver cancerDifferential survival outcomesHealthcare Common Procedure Coding SystemCause mortalityCause survivalLiver transplantMachine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study.
Iseke S, Zeevi T, Kucukkaya AS, Raju R, Gross M, Haider SP, Petukhova-Greenstein A, Kuhn TN, Lin M, Nowak M, Cooper K, Thomas E, Weber MA, Madoff DC, Staib L, Batra R, Chapiro J. Machine Learning Models for Prediction of Posttreatment Recurrence in Early-Stage Hepatocellular Carcinoma Using Pretreatment Clinical and MRI Features: A Proof-of-Concept Study. American Journal Of Roentgenology 2022, 220: 245-255. PMID: 35975886, PMCID: PMC10015590, DOI: 10.2214/ajr.22.28077.Peer-Reviewed Original ResearchConceptsEarly-stage hepatocellular carcinomaLiver transplantHepatocellular carcinomaImaging featuresPosttreatment recurrenceOrgan allocationMean AUCLiver transplant eligibilityPretreatment clinical characteristicsPretreatment MRI examinationsKaplan-Meier analysisKaplan-Meier curvesClinical characteristicsImaging surveillanceTherapy allocationTransplant eligibilityUnderwent treatmentClinical parametersRetrospective studyUnpredictable complicationMRI dataConcept studyPoor survivalClinical impactPretreatment MRIRandomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular And Interventional Radiology 2022, 45: 405-412. PMID: 35119481, PMCID: PMC8940827, DOI: 10.1007/s00270-021-03031-9.Peer-Reviewed Original ResearchConceptsBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseHepatocellular carcinomaCurative treatmentRECIST 1.1Primary endpointClinical benefitControl rateEastern Cooperative Oncology Group performance status 0Response rateChild-Pugh class ARandomized phase 3 studyDual primary endpointsOverall survival eventsPerformance status 0Previous systemic treatmentPD-1 inhibitorsPortal vein thrombosisPhase 3 studyResponse Evaluation CriteriaSolid Tumors 1.1LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
El-Khoueiry A, Llovet J, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2022, 40: tps494-tps494. DOI: 10.1200/jco.2022.40.4_suppl.tps494.Peer-Reviewed Original ResearchBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseTransarterial chemoembolizationRECIST v1.1Hepatocellular carcinomaEnd pointCurative treatmentEastern Cooperative Oncology Group performance statusDual primary end pointsExploratory end pointsPrevious systemic treatmentPD-1 inhibitorsPortal vein thrombosisPrimary end pointSecondary end pointsSecond-line therapyPhase 3 studyHealth-related qualityIntermediate hepatocellular carcinomaAdvanced hepatocellular carcinomaLimited treatment options
2021
Balloon-assisted radioembolization via the proper hepatic artery to treat a left liver hepatocellular carcinoma and portal vein tumor thrombus with an inaccessible left hepatic artery: A case report
Mabey JG, Cornman-Homonoff J, Madoff DC. Balloon-assisted radioembolization via the proper hepatic artery to treat a left liver hepatocellular carcinoma and portal vein tumor thrombus with an inaccessible left hepatic artery: A case report. Clinical Imaging 2021, 82: 244-250. PMID: 34920388, DOI: 10.1016/j.clinimag.2021.11.026.Peer-Reviewed Case Reports and Technical NotesConceptsPortal vein tumor thrombusLeft hepatic arteryProper hepatic arteryHepatic arteryVein tumor thrombusHepatocellular carcinomaTransarterial radioembolizationTumor thrombusUse of TAREYttrium-90 transarterial radioembolizationTumor-feeding vesselsLiver hepatocellular carcinomaBalloon occlusionCase reportBalloon microcatheterVessel angulationEffective treatmentLiver parenchymaArteryTumor vesselsY microspheresRadiotracer activityRadioembolizationCarcinomaThrombusThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient groupInternational recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres
Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der veen BJ, Flamen P. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1570-1584. PMID: 33433699, PMCID: PMC8113219, DOI: 10.1007/s00259-020-05163-5.Peer-Reviewed Original ResearchConceptsSelective internal radiation therapyInternal radiation therapyActivity prescriptionRadiation therapyLiver metastatic colorectal cancerYttrium-90 resin microspheresResin microspheresMetastatic liver diseaseMetastatic colorectal cancerMultidisciplinary expert panelNon-tumoural liverSPECT/CTLiver diseaseColorectal cancerTreatment strategiesHepatocellular carcinomaSteering CommitteePost-treatment dosimetryYttrium-90Multidisciplinary teamTherapeutic intentMicrosphere activityWhole liverLiterature searchLevel of agreement
2020
Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions
Aslam A, Gian R, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World Journal Of Hepatology 2020, 12: 738-753. PMID: 33200013, PMCID: PMC7643220, DOI: 10.4254/wjh.v12.i10.738.Peer-Reviewed Original ResearchTreatment response algorithmLI-RADS treatment response algorithmLocoregional therapyLiver Imaging ReportingHepatocellular carcinomaTreatment response assessmentTreatment optionsResponse assessmentData System treatment response algorithmImaging ReportingDifferent locoregional therapiesLiver transplant candidacyHCC treatment responseTransplant candidacyOverall survivalSystemic therapyTumor burdenLeading causeTreatment responseLI-RADSTumor assessmentEconomic burdenClinical practiceTumor progressionTherapyLEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ogasawara S, Ren Z, Mody K, Li J, Siegel A, Dubrovsky L, Kudo M. LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Annals Of Oncology 2020, 31: s702-s703. DOI: 10.1016/j.annonc.2020.08.1132.Peer-Reviewed Original ResearchP-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
Ogasawara S, Llovet J, El-Khoueiry A, Vogel A, Madoff D, Finn R, Ren Z, Modi K, Li J, Siegel A, Dubrovsky L, Kudo M. P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Annals Of Oncology 2020, 31: s124-s125. DOI: 10.1016/j.annonc.2020.04.189.Peer-Reviewed Original ResearchEmbolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers 2020, 12: 791. PMID: 32224882, PMCID: PMC7226474, DOI: 10.3390/cancers12040791.Peer-Reviewed Original ResearchStage hepatocellular carcinomaSelective internal radiotherapyAdvanced-stage hepatocellular carcinomaTrans-arterial chemoembolizationHepatocellular carcinomaRecent large prospective trialsSimilar disease control rateManagement of HCCEarly-stage hepatocellular carcinomaStage of HCCDisease control rateSystemic treatment optionsLarge prospective trialsLocal disease controlCancer-related morbidityArterial therapyProspective trialImproved tolerabilityPalliative optionControl rateTreatment optionsTherapeutic strategiesDisease controlInternal radiotherapyTolerability3:00 PM Abstract No. 32 Ablation versus surgical resection for small hepatocellular carcinoma: a risk-adjusted SEER-Medicare analysis
Charalel R, Mao J, Li S, Kwan S, Brunner M, Talenfeld A, Madoff D, Abramson E, Fortune B, Ibrahim S, Mushlin A, Sedrakyan A. 3:00 PM Abstract No. 32 Ablation versus surgical resection for small hepatocellular carcinoma: a risk-adjusted SEER-Medicare analysis. Journal Of Vascular And Interventional Radiology 2020, 31: s18-s19. DOI: 10.1016/j.jvir.2019.12.054.Peer-Reviewed Original Research